# Burkitt Lymphoma Genome Sequencing Project (BLGSP)

**Instructions:** This form should be completed for all cases submitted for BLGSP, prior to the shipment of samples to Nationwide Children's Hospital.

## Questions regarding this form should be directed to the Office of Cancer Genomics (OCG).

Tissue Source Site (TSS) acknowledges that the Biospecimen Processing Core (BPC) will assess the tissue quality of the frozen biospecimen to determine whether it meets the metrics required by BLGSP. If the BPC identifies a possible discrepancy, the TSS authorizes the BPC to report these results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.

Tissue Source Site (TSS):	TSS Identifier:	TSS Unique Patient Identifier:	
Completed by (interviewer name in OpenClinica):	Completed Date:///		

## **Verification of BLGSP Requirements**

Prior to the shipment of samples to the BPC, the TSS must answer the following questions to verify that BLGSP requirements are met. For a complete list of requirements, please contact the Office of Cancer Genomics.

#	Question	Entry Alternatives	Working Instructions
1*	BLGSP Patient Identifier		The patient identifier is part of the BLGSP identifier is provided by the OCG project office and is defined below:  Example: BLGSP-71-05-12345-01-A  BLGSP: The Burkitt Lymphoma Genome Sequencing Project 71: Disease Code for Non-Hodgkin's Lymphoma, Burkitt lymphoma 05: Tissue Source Site Identifier 12345: Sample/Patient Identifier 01: This defines the type of sample submitted. A: This defines the aliquot/portion of the sample submitted. Please provide only the patient identifier, not the entire BLGSP identifier.
2*	Tumor Type	☐ Primary Untreated Malignant Tumor Tissue ☐ Metastatic Malignant Tumor Tissue ☐ Recurrent Malignant Tumor Tissue ☐ Additional Primary Malignant Tumor Tissue	Indicate the tumor category of the tumor submitted for BLGSP.  If tumor type is other than primary untreated malignant tumor tissue, contact OCG for assistance.  3288124
3*	Histological Subtype	☐ Burkitt Lymphoma	Indicate the histologic subtype for the tumor sample being submitted. 3081934
4*	Burkitt Lymphoma Clinical Variant	☐ Sporadic, Adult ☐ Sporadic, Pediatric ☐ Endemic ☐ Immunodeficiency-associated, Adult ☐ Immunodeficiency-associated, Pediatric	Provide the clinical variant of the Burkitt Lymphoma case submitted for BLGSP. 3770421
5*	History of Other Malignancy (Including ALL Prior and Synchronous Malignancies)	☐ Yes (exclusionary, see note at right) ☐ No	Indicate whether the patient has a history of malignancies, including synchronous or bilateral malignancies. If the patient has a prior or synchronous malignancy, excluding in situ cervical cancer or non-melanoma skin cancer, the case is not eligible for BLGSP. 3382736  In situ cervical cancer and non-melanoma skin cancer are allowable.
6*	History of Neoadjuvant Treatment (prior to procurement) of Tumor Submitted for BLGSP	☐ Yes (exclusionary, see note at right)☐ No	Indicate whether the patient received therapy for the tumor submitted for BLGSP prior to the sample procurement. If the patient did receive treatment prior to procurement, the case is not eligible for BLGSP.  Any systemic or localized (those administered to the same site as the BLGSP submitted tissue) therapies given prior to the procurement of the sample submitted for BLGSP are

exclusionary. 3382737

Page 2	Sample Submission Form	V5.26 05012017
--------	------------------------	----------------

Burkitt Lymphoma Genome Sequencing Project (BLGSP)

#	Question	Entry Alternative	s	Working Instructions
7*	Consent Status	☐ Formally Consented ☐ Consented by Death ☐ Exemption (see note at right) ☐ Waiver (see note at right)		Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent.  Exemptions and waivers for consent must be approved by OCG.  3288361
8†	Date of Formal Consent	Month Day	Year	If the patient was formally consented, provide the month of consent. 3081955 (month), 3081957 (day), 3081959 (year)
9†	Date of Death	Month Day	Year	If the patient consented by death (i.e. they did not formally consent), provide the month of death.  Do not complete if the patient formally consented.  2897026 (month), 2897028 (day), 2897030 (year)

### **Tumor Information**

The following information must be completed for the tumor sample submitted for BLGSP and should be answered specifically about the submitted sample(s). If multiple vials of the tumor sample are submitted, the "Tumor Sample Information" must be completed for each vial submitted to the BPC.

# The tumor sample ID is part of the BLGSP identifier is provided by the OCG project office and is defined below:

**BLGSP**: The Burkitt Lymphoma Genome Sequencing Project

71: Disease Code for Non-Hodgkin's Lymphoma, Burkitt lymphoma

**05**: Tissue Source Site Identifier **12345**: Sample/Patient Identifier

**01**: This defines the type of sample submitted (i.e. primary tumor = 01, normal blood =10). For a complete list see BLGSP SOP #007.

A: This defines the aliquot/portion of the sample submitted. If multiple portions of the same sample are submitted they would have multiple IDs with A, B, C, etc. added to the sample ID.

10*	11*	12*	13*	14†	
Tumor Sample ID	Vial ID	Tumor Sample Type	Preservation Method	Total Number of Cells Counted	
3288096	2186575	3812626	5120693	2006887	
Provide the TSS unique tumor	Provide the vial ID. If multiple vials	Indicates whether the physical tumor sample submitted was provided	The method used to preserve	If sorted cells were submitted, provide	
ID. If multiple pieces of tumor	are submitted, each tumor sample		the sample.	the number of cells counted.	
are submitted, each tumor	needs a unique ID.	from a FFPE block, or an unstained slide.			
sample needs a unique ID.					
	$\square A \square B \square C \square D \square E$	□ Portion	FFPE		
	OF OG OH OI OJ	□ Block	☐ Frozen		
	OK OL OM ON OO	□ Scroll			
		☐ Unstained Slide			
		☐ Sorted Cells (please provide flow cytometry report, see #19)			
	$\square A \square B \square C \square D \square E$	□ Portion	☐ FFPE		
	OF OG OH OI OJ	□ Block	☐ Frozen		
	OK OL OM ON OO	□ Scroll			
	$\square P \square Q \square R \square S \square T$	☐ Unstained Slide			
		☐ Sorted Cells (please provide flow cytometry report, see #19)			
	$\square A \square B \square C \square D \square E$	□ Portion	☐ FFPE		
	OF OG OH OI OJ	□ Block	☐ Frozen		
	OK OL OM ON OO	□ Scroll			
		☐ Unstained Slide			
		☐ Sorted Cells (please provide flow cytometry report, see #19)			

#	Question			Working Instructions		
15*	Method of Tumor Sample Procurement	☐ Bone Marrow Aspirate ☐ Excisional Biopsy ☐ Incisional Biopsy ☐ Needle Biopsy ☐ Surgical Resection ☐ Other (Please Specify)		Indicate the procedure performed to obtain the malignant tissue submitted for BLGSP. 3103514		
16 <sup>†</sup>	Other Method of Tumor Sample Procurement			If the procedure performed to obtain the malignant tissue is not included in the provided list, indicate the procedure performed. $\underline{2006730}$		
17*	Anatomic Site of Frozen Biospecimen	□ Adrenal Gland □ Appendix □ Ascites □ Bladder □ Bone □ Bone Marrow □ Brain □ Breast □ Colon □ Epididymis □ Epidural Space □ Esophagus □ Eye □ Gallbladder □ Heart □ Kidney □ Larynx □ Leptomeninges □ Liver □ Lung □ Lymph Node(s), axillary □ Lymph Node(s), femoral □ Lymph Node(s), femoral □ Lymph Node(s), hilar □ Lymph Node(s), hilar □ Lymph Node(s), hilar □ Lymph Node(s), iliac □ Lymph Node(s), iliac □ Lymph Node(s), mediastinal □ Lymph Node(s), mesenteric □ Lymph Node(s), paraaortic □ Lymph Node(s), paraaortic □ Lymph Node(s), paratid □ Lymph Node(s), popliteal □ Lymph Node(s), popliteal □ Lymph Node(s), popliteal □ Lymph Node(s), retroperitoneal	□ Lymph Node(s), splenic □ Lymph Node(s), submandibular □ Lymph Node(s), supraclavicular □ Mandible □ Maxilla □ Mediastinal Soft Tissue □ Nasal Soft Tissue □ Nasopharynx □ Ocular orbits □ Oral Cavity □ Oropharynx □ Ovary □ Pancreas □ Parotid Gland □ Pericardium □ Peri-orbital Soft Tissue □ Peripheral Blood □ Pleura □ Prostate □ Rectum □ Salivary Gland □ Sinus(es) □ Skin □ Small Intestine □ Soft Tissue (muscle, ligaments, subcutaneous) □ Stomach □ Testicle □ Thymus □ Thyroid gland □ Uterus □ Other, please specify	Indicate the anatomic site of the frozen biospecimen tumor tissue sample. 4742851		
18 <sup>†</sup>	Other Anatomic Site of Frozen Biospecimen			Name of the anatomic site of a frozen biospecimen that is different from those already specified.  4742871		
19*	Date of Tumor Sample Procurement	Month Day	Year	Provide the date of the procedure performed to obtain the malignant tissue submitted for BLGSP. 3008197 (month), 3008195 (day), 3008199 (year)		

Pag	Page 4 Sample Submission Form Burkitt Lymphoma Genome Sequencing Project (BLGSP)														
20	De-Identified Reports Associated with Tumor Sample	With Attach <u>De-Identified</u> Reports in OpenClinica or Submit to the BPC						immunc	orts may ohistocho ould be d	emistry	reports,	etc.			ogy
Tumor Slide Information The following information must be completed if slides are submitted for BLGSP tumor samples. If multiple slides are submitted, ALL QUESTIONS should be compslide.						mplete	d for	each							
21*			22*												
Type	(s) of Slides Submitted (select only one f	for each ID)	Slide	or Dig	ital Ima	age ID									
3521	909		2321	277											
The ty	ype of slide submitted, which includes both the did be answered for each tumor slide submitted.	preservation method and format of the slide. This question	The id	entifier	for the s	lide or d	igital im	age pro	vided to	the BPC	J.				
	Physical Slide - Frozen Top Slide	☐ Digital Slide Image - Frozen Top Slide													
	Physical Slide - FFPE Top Slide	☐ Digital Slide Image - FFPE Top Slide													
	Physical Slide - FFPE Diagnostic Slide	☐ Digital Slide Image - FFPE Diagnostic Slide													
	Physical Slide - Frozen Top Slide	☐ Digital Slide Image - Frozen Top Slide													
	Physical Slide - FFPE Top Slide	☐ Digital Slide Image - FFPE Top Slide													
	Physical Slide - FFPE Diagnostic Slide	☐ Digital Slide Image - FFPE Diagnostic Slide													
	Physical Slide - Frozen Top Slide	☐ Digital Slide Image - Frozen Top Slide													
	Physical Slide - FFPE Top Slide	☐ Digital Slide Image - FFPE Top Slide													
	Physical Slide - FFPE Diagnostic Slide	☐ Digital Slide Image - FFPE Diagnostic Slide													
norma		ted for the normal control sample submitted for BI JESTIONS should be completed for each sample. If r each vial submitted to the BPC.													
23*			24*												
	nal Control ID		Vial ID												
3288			2186575  a Provide the vial ID. If multiple vials are submitted, each normal sample needs a unique ID.												
Provid uniqu		ll control samples are submitted, each normal control needs a	Provid	le the vi	al ID. If r	multiple	vials ar	e submi	tted, eac	h norma	al sampl	e needs a	a unique	ID.	
uniqu	CID.		ПΑ	□в	□с	□D	ΠЕ	□F	□G	ΠН	ΠI	ΠJ	□к	□L	□м
					□Р	□Q	□R		ПΤ	U	$\Box V$	□W	$\square X$	ПΥ	$\Box$ Z
				$\square$ B	□С		□E	□F	□G	ПН			□К		$\square$ M
					□Р	□Q	□R		ПΤ	U		□W			
								□ F	G	ПН			□ K		
					□Р	□Q	□R		ПТ	U	$\Box v$	□W		ПΥ	
#	Question	Entry Alternatives							tructio						
25*	Type(s) of Normal Control(s) Check all that apply	□ Whole Blood* □ Buccal Cells □ Granulocytes □ Lymphocytes (buffy coat)* □ Extracted DNA from Blood* □ Extracted DNA from Buccal Cells □ Mononuclear Cells from Bone Marrow Normal □ Normal Tissue													
□ Normal Tissue □ Sorted Cells (please provide flow cytometry report, see															

Page 5	Sample Submission Form	V5.26 05012017
	Burkitt Lymphoma Genome Sequencing Project (BLGSP)	

26*	Method of Normal Control Procurement	□ Blood Draw       □ Bone Marrow Aspirate         □ Buccal Swab       □ Surgical Resection         □ Mouthwash       □ Other			Indicate the procedure performed to obtain the normal control sample submitted for BLGSP. $\underline{3288147}$
27 <sup>†</sup>	Other Method of Normal Control Procurement				If the method used to collect the normal control is not included in the provided list, specify the method used. $\underline{3288151}$
28*	Date of Normal Control Procurement	Month	 Day	Year	Provide the date of the procedure performed to obtain the normal control submitted for BLGSP.  3288195 (month), 3288196 (day), 3288197 (year)
29†	Extracted DNA Quantity of Normal Control	_		If the normal control type is extracted DNA, provide the quantity ( $\mu g$ ) of the normal control sample sent to the BPC for BLGSP. $3288185$	
30†	Extracted DNA Quantification Method of Normal Control				If the normal control type is extracted DNA, provide the quantification method of the normal control sample sent to the BPC for BLGSP. 3288186
31 <sup>†</sup>	Extracted DNA Concentration of Normal Control		(μ	If the normal control type is extracted DNA, provide the concentration ( $\mu g/\mu L$ ) of the normal control sample sent to the BPC for BLGSP. 3288187	
32†	Extracted DNA Volume of Normal Control	_		(μL)	If the normal control type is extracted DNA, provide the volume ( $\mu L$ ) of the normal control sample sent to the BPC for BLGSP. $\underline{3288188}$
33†	Anatomic Site of Normal Sample	☐ Appendix☐ Blood☐ Colon☐ Gallbladder☐ Liver☐	☐ Lymph Node(s) ☐ Muscle ☐ Pancreas ☐ Skin ☐ Small Intestine	☐ Spleen ☐ Stomach ☐ Tonsil ☐ Other, please specify	If the normal control type is normal tissue or sorted cells, indicate the anatomic site of the non-neoplastic control tissue submitted for BLGSP.  4132152
34 <sup>†</sup>	Other Anatomic Site of Normal Sample				Text to describe another anatomic site of the normal tissue not previously mentioned or specified.  3288189
35†	Distance of Normal Tissue from Tumor	☐ Adjacent (< or = 2 cr ☐ Distal (> 2 cm) ☐ Unknown	n) (exclusionary , see note at right,	If the normal control type is normal tissue or sorted cells, confirm that the submitted tissue was at least 2cm away from the primary tumor.  Adjacent (≤ 2cm) normal tissue is not accepted.  If the proximity of the non-neoplastic control tissue from the submitted tumor is unknown, the tissue will be excluded.  3088708	
36†	Total Number of Cells Counted for the Normal Sample			If the normal control type is sorted cells, provide the number of cells counted. $\underline{5260823}$	
37	De-Identified Reports Associated with Normal Sample	Attach <u>De-Identi</u>	fied Reports in OpenClinica (	Associated reports may include: flow cytometry report, pathology report, immunohistochemistry reports, etc.  All reports should be de-identified prior to sending to the BPC.	

Questions required for submission